Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018)

Bretagne, Stéphane; Sitbon, Karine; Desnos‐Ollivier, Marie; García-Hermoso, Dea; Letscher-Bru, Valérie; Cassaing, Sophie; Millon, Laurence; Morio, Florent; Gangneux, Jean‐Pierre; Hasseine, Lilia; Favennec, Loïc; Cateau, Estelle; Bailly, Éric; Moniot, Maxime; Bonhomme, Julie; Desbois‐Nogard, Nicole; Chouaki, Taïeb; Paugam, A.; Bouteille, Bernard; Pihet, Marc; Dalle, Frédéric; Éloy, O.; Sasso, Milène; Demar, Magalie; Mariani‐Kurkdjian, Patricia; Robert, Vincent; Lortholary, Olivier; Dromer, Françoise; Damiani, Céline; Dupont, Hervé; Maizel, Julien; Totet, Anne; Bouchara, Jean-Philippe; Bellanger, Anne Pauline; Berceanu, Ana; Navellou, Jean Christophe; Scherer, Émeline; Abboud, Philippe; Aznar, Christine; Blanchet, Denis; Djossou, Félix; Cayot, Sophie; Garrouste, Cyril; Lesens, Olivier; Moluçon, Cécile; Nourrisson, Céline; Poirier, Philippe; Bailly, Éloïse; Basmaciyan, Louise; Belaid, Bouhemad; Blot, Mathieu; Caillot, Denis; Charles, Pierre‐Emmanuel; Quenot, Jean‐Pierre; Amazan, E.; Baubion, É.; Cabie, André; Chabartier, Cyrille; Deligny, C.; Emal, Violaine; Flechelle, Olivier; Hatchuel, Yves; Govic, Yohann Le; Merle, H.; Miossec, Charline; Turmel, Jean-Marie; Valentino, Ruddy; Durieux, Marie‐Fleur; Turlure, Pascal; Mercier, Victor; Gari-Toussaint, M.; Risso, Karine; Simon, Loïc; Bretonnière, Cédric; Boutoille, David; Gastinne, Thomas; Lakhal, Karim; Launay, Élise; Lepoivre, Thierry; Péterlin, Pierre; Rialland, Fanny; Pape, Patrice Le; Canouï, Etienne; Dahane, Naïma; Kerneis, Solène; Angebault, Cécile; Bougnoux, Marie-Elisabethh; Guennouni, Nadia; Lanternier, Fanny; Neven, Bennedicte; Oualha, Mehdi; Scemla, Anne; Sitterlé, Emilie; Suarez, Félipe; Toubiana, Julie; Bonacorci, Stéphane; Alanio, Alexandre; Bergeron, Anne; Denis, Blandine; Gits-Muselli, Maud; Hamane, Samia; Touratier, S.; Chaumeil, C.; Merabet, Lilia; Claudéon, Joelle; Curlier, Elodie; Galantine, Valérie; Gallois, Jean Claude; Markowicz, Samuel; Nicolas, M.; Musson, Pascal; Schepers, Kinda; Minoza, Alida; Kauffmann‐Lacroix, C.; Guegan, Hélène; Costa, Damien; Dehais, Marion; Gargala, Gilles; Bajolet, Odile; Bani-Sadr, F.; Cousson, J.; Himberlin, Chantal; Huguenin, A; Toubas, D.; Flori, Pierre; Mahinc, Caroline; Rabérin, H.; Denis, Julie; Herbrecht, Raoul; Mertès, Paul-Michel; Meziani, Fehrat; Sabou, Marcela; Schneider, Francis; Bertozzi, Anne‐Isabelle; Chauvin, Pamela; Charpentier, Éléna; Cointault, Olivier; Cottrel, Claire; Delavigne, K.; Faguer, Stanislas; Fillaux, Judith; Guemas, Emilie; Iriart, Xavier; Lelièvre, L; Ruiz, Jean; Bastides, Frédéric; Chesnay, Adélaïde; Désoubeaux, Guillaume; Therby, A.; Chachaty, Élisabeth; Gachot, Bertrand

doi:10.1128/mbio.00920-22

Cited by 38 publications

(26 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RESSIF network was started in 2012 by the French National Reference Center for Invasive Mycoses and Antifungals (NRCMA, Institut Pasteur, Paris, France). 24 It is an active surveillance system involving 29 participating secondary and tertiary centres across metropolitan France and overseas French territories, with 21 centres who were active between 2013 and 2018 (and 13 centres in 2012). All IFDs occurring in these centres are prospectively and manually notified.…”

Section: Methodsmentioning

confidence: 99%

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

et al. 2023

Self Cite

View full text Add to dashboard Cite

ObjectivesWe aimed to describe patients with autoimmune diseases (AID) developing invasive fungal disease (IFD) and identify factors associated with short-term mortality.MethodsWe analysed cases of IFD associated with AID from the surveillance network of invasive fungal diseases (Réseau de surveillance des infections fongiques invasives, RESSIF) registry of the French national reference centre for invasive mycoses. We studied association of AID-specific treatments with 30-day mortality. We analysed total lymphocyte and CD4-T cell counts in patients withPneumocystis jiroveciipneumonia (PCP).ResultsFrom 2012 to 2018, 549 individuals with IFD and AID were included, mainly with PCP (n=227, 41.3%), fungemia (n=167, 30.4%) and invasive aspergillosis (n=84, 15.5%). Rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV) were the most frequent AID in PCP (n=55 and 25, respectively) and invasive aspergillosis (n=15 and 10, respectively), inflammatory bowel diseases (IBDs) were predominant in fungemia (n=36). At IFD diagnosis, 365 (66.5%) patients received glucocorticoids (GCs), 285 (51.9%) immunosuppressants, 42 (7.7%) tumor necrosis factor (TNF)-α blockers, 75 (13.7%) other biologics. Mortality at 30 days was 28.1% (143/508). Fungemia and high-dose GCs were independently associated with higher 30-day mortality. In PCP patients, lymphopenia <1500/mm3was frequent (132/179, 73.7%) even if CD4+T cell count exceeded 200/mm3in 56/78 patients (71.8%) (median 472.5/mm3, IQR 160–858).ConclusionIFD associated with AID occurs primarily in RA, AAV and IBD, especially when treated with GCs and immunosuppressants. Mortality is high, especially for patients on high-dose GCs. Lymphopenia may help identify risk of PCP, but normal CD4+T cell count does not rule out the risk. Further studies are needed to assess the individual risk factors for IFD.

show abstract

Section: Methodsmentioning

confidence: 99%

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mucormycosis is a rare but life-threatening invasive fungal infection caused by filamentous fungi of the order Mucorales. The incidence of mucormycosis has increased from 0.07 to 0.12 per 100,000 population during 2001–2010 in France; currently mucormycosis is the fourth most common cause of invasive fungal disease after fungemia, pneumocystosis and invasive aspergillosis [ 1 , 2 ]. This trend of increasing mucormycosis has also been reported by other European countries such as Spain, Switzerland, and Belgium [ 3 , 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…This trend of increasing mucormycosis has also been reported by other European countries such as Spain, Switzerland, and Belgium [ 3 , 4 , 5 , 6 ]. An active surveillance program by the French surveillance network of invasive fungal infections (RESSIF) has reported the incidence of mucormycosis remained stable between 2012 and 2018 [ 2 ]. In an autopsy series, mucormycosis had a frequency of 1–5 cases per 10,000 autopsies, which was 10–50 folds less frequent than invasive candidiasis or aspergillosis [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

What Is New in Pulmonary Mucormycosis?

Danion

Coste

Hyaric

et al. 2023

JoF

Self Cite

View full text Add to dashboard Cite

Mucormycosis is a rare but life-threatening fungal infection due to molds of the order Mucorales. The incidence has been increasing over recent decades. Worldwide, pulmonary mucormycosis (PM) presents in the lungs, which are the third main location for the infection after the rhino-orbito-cerebral (ROC) areas and the skin. The main risk factors for PM include hematological malignancies and solid organ transplantation, whereas ROC infections classically are classically favored by diabetes mellitus. The differences between the ROC and pulmonary locations are possibly explained by the activation of different mammalian receptors—GRP78 in nasal epithelial cells and integrin β1 in alveolar epithelial cells—in response to Mucorales. Alveolar macrophages and neutrophils play a key role in the host defense against Mucorales. The diagnosis of PM relies on CT scans, cultures, PCR tests, and histology. The reversed halo sign is an early, but very suggestive, sign of PM in neutropenic patients. Recently, the serum PCR test showed a very encouraging performance for the diagnosis and follow-up of mucormycosis. Liposomal amphotericin B is the drug of choice for first-line therapy, together with correction of underlying disease and surgery when feasible. After a stable or partial response, the step-down treatment includes oral isavuconazole or posaconazole delayed release tablets until a complete response is achieved. Secondary prophylaxis should be discussed when there is any risk of relapse, such as the persistence of neutropenia or the prolonged use of high-dose immunosuppressive therapy. Despite these novelties, the mortality rate from PM remains higher than 50%. Therefore, future research must define the place for combination therapy and adjunctive treatments, while the development of new treatments is necessary.

show abstract

“…Hematological malignancies are the main underlying diseases associated with mucormycosis. The available data suggest that mucormycosis has the highest mortality rate among all types of fungal infections ( Bretagne et al., 2022 ), whereas hematologic malignancies ranked the first in the mortality of all primary diseases among mucormycosis patients ( Roden et al., 2005 ; Muthu et al., 2021 ). Mucormycosis has thus become one of the most important causes of death in patients with hematologic malignancies.…”

Section: Introductionmentioning

confidence: 99%

Amphotericin B colloidal dispersion: an effective drug for the treatment of mucormycosis in China

Liu

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

ObjectiveMucormycosis has emerged as an increasingly important cause of morbidity and mortality in immunocompromised patients, but the effective drugs for the treatment are limited. Hence, the study aimed to summarize the characteristics of mucormycosis in patients with hematological malignancies, and investigate the efficacy and safety of Amphotericin B Colloidal Dispersion (ABCD) in treating mucormycosis.MethodsIn this study, patients with mucormycosis complicated by hematological malignancies who received ABCD at the First Affiliated Hospital of Zhengzhou University from April 2021 to May 2022 were retrospectively enrolled. The clinical data of the enrolled patients were collected, and then, the drug response at 2 weeks, 4 weeks, and the end of treatment; the survival rate at 4, 8, and 12 weeks; and the laboratory-related indicators and adverse events (AEs) associated with ABCD were evaluated.ResultsIn total, 9 patients with mucormycosis complicated by hematological malignancies were enrolled. The main symptoms were fever, cough, and chest pain. In addition, reversed halo signs (RHS) were found on chest CTs. The responses to ABCD at 2 weeks, 4 weeks, and the end of treatment were 100% (9/9), 77.8% (7/9), and 77.8% (7/9), respectively. The survival rates of the patients at 4, 8, and 12 weeks were 77.8% (7/9), 66.7% (6/9), and 66.7% (6/9), respectively. Among laboratory-related indicators, white blood cell (WBC) counts were significantly increased from baseline after 1 and 2 weeks of ABCD treatment (P<0.05), whereas neutrophil counts were only increased significantly from baseline at 2 weeks post-treatment (P<0.05). The most common AEs were infusion-related AEs manifesting as fever, chills, and pruritus. Moreover, none of the patients suffered from renal injury once again.ConclusionABCD is a promising treatment strategy for patients with mucormycosis complicated by hematologic malignancies, showing remarkable efficacy and safety.

show abstract

Active Surveillance Program to Increase Awareness on Invasive Fungal Diseases: the French RESSIF Network (2012 to 2018)

Cited by 38 publications

References 42 publications

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

Invasive fungal diseases in patients with autoimmune diseases: a case series from the French RESSIF network

What Is New in Pulmonary Mucormycosis?

Amphotericin B colloidal dispersion: an effective drug for the treatment of mucormycosis in China

Contact Info

Product

Resources

About